Ovarian Cancer Clinical Trials in Maryland

Showing 201-220 of 243 trials

Immunotoxin Therapy in Treating Patients With Advanced Cancer

NCT00006981

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer. PURPOSE: Phase I trial to study the effectiveness of immunotoxins in treating patients who have advanced cancer.

Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more

National Cancer Institute (NCI)Started Dec 2000

Bethesda, Maryland, United States

COMPLETEDPhase 217 miles

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

NCT00039585

RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have refractory or relapsed ovarian epithelial, fallopian tube, or primary peritoneal cancer, or ovarian low malignant potential tumor.

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

National Cancer Institute (NCI)Started May 2002

Bethesda, Maryland, United States • Bethesda, Maryland, United States

COMPLETEDPhase 117 miles

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

NCT00019136

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus gene-modified white blood cells in treating patients who have advanced ovarian epithelial cancer.

Ovarian Cancer

National Cancer Institute (NCI)Started Feb 1997

Bethesda, Maryland, United States

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Ovarian Cancer Trials in Other Cities

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Other Conditions in Maryland